BridgeMD
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)
EU CTIS ID: 2025-522713-29-00
What this study is testing
To determine whether treatment with pasritamig+docetaxel prolongs rPFS compared with docetaxel in participants with mCRPC
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Have progressive metastatic castrate-resistant disease defined as at least one of the following: - PSA level ≥2 ng/mL that has increased on at least 2 successive occasions at least 1 week apart. - Progressive disease or new lesion(s) in the lymph nodes, bones, or viscera as defined by RECIST v1.1 and/or in bone scan per PCWG3 while on medical or surgical castration.
- 2. Have progressed on at least 1 novel ARPI but received no more than 2 different ARPI (eg, abiraterone acetate, apalutamide, enzalutamide, darolutamide) for any stage of disease. Must have discontinued ARPI before randomization into the study.
- 3. Have the following laboratory values during the screening period: - Hemoglobin ≥9.0 g/dL - Neutrophils ≥1.5 x 10^9/L - Platelets ≥100 x 10^9/L Note, transfusion or growth factor usage within 14 days of randomization is not allowed.
You likely can't join if
- 1. Received cytotoxic chemotherapy for prostate cancer (eg, docetaxel, cabazitaxel, mitoxantrone, etc).
- 2. Received prior treatment for prostate cancer with: - CD3 redirector therapies or - Radiopharmaceutical agents or - Immunotherapy agents for prostate cancer (eg, sipuleucel-T, PD-1 inhibitors, T-cell redirectors, costimulatory agents, etc) or - PARP inhibitors (unless for BRCA1/2 mutations) or - Any other investigational agent for the treatment of mCRPC
- 3. Patients with known BRCA 1/2 mutations (germline or somatic) who have not received treatment with a PARP inhibitor, unless not available or contraindicated.
The study team makes the final eligibility decision.
Where it's taking place
- Brazil
- Taiwan
- Australia
- Japan
- United Kingdom
- Turkey
- China
- Canada
- United States
- Korea, Republic of
- Malaysia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brazil; Taiwan; Australia; Japan; United Kingdom; Turkey and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.